Compare Occidental Petroleum Corporation (OXY) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Occidental Petroleum Corporation vs Travere Therapeutics Inc. Common Stock — how do they compare? Occidental Petroleum Corporation trades at $61.76 (market cap $61.39B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $5.02B). The key difference: Occidental Petroleum Corporation is far larger — about 12.2× Travere Therapeutics Inc. Common Stock's market cap, and Occidental Petroleum Corporation pays a 1.82% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Occidental Petroleum Corporation for 92 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| OXY | TVTX | |
|---|---|---|
Market Cap | $61.39B | $5.02B |
Volume | 8,708,264 | 2,060,842 |
Sector | Energy | Health |
52-Week High | $66.24 | $67.52 |
52-Week Low | $38.92 | $26.79 |
Typical Hold Time | 92 Days | 0 Days |
Enterprise Value | $80.15B | $5.15B |
Dividend Yield | 1.82% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Occidental Petroleum (OXY) trades at $61.65, up 0.85% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $70.92. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected soon. Financials show strong profitability with a 30.32% net income margin and robust cash flow, though revenue has declined from 2022 peaks. Recent news highlights focus on dividend reliability and Goldman Sachs' upgrade citing cash flow targets and debt reduction.
OXY presents a favorable outlook with earnings momentum, attractive valuation multiples, and analyst support, but faces risks from oil price volatility and competitive pressures. The stock's upside potential hinges on execution of debt reduction and sustained operational efficiency amid energy market fluctuations.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Occidental Petroleum Corporation
Occidental Petroleum is an independent exploration and production company with operations in the United States, Latin America, and the Middle East. At the end of 2021, the company reported net proved reserves of 3.5 billion barrels of oil equivalent. Net production averaged 1,174 thousand barrels of oil equivalent per day in 2021 at a ratio of 75% oil and natural gas liquids and 25% natural gas.
Read more on OXY →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
